• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

亚种HN019活益生菌和后生元:潜在治疗特性的生产策略及生物活性评估

subsp. HN019 live probiotics and postbiotics: production strategies and bioactivity evaluation for potential therapeutic properties.

作者信息

D'ambrosio Sergio, Dabous Azza, Sadiq Saba, Casillo Angela, Schiraldi Chiara, Cassese Elisabetta, Bedini Emiliano, Corsaro Maria Michela, Cimini Donatella

机构信息

Department of Environmental, Biological and Pharmaceutical Sciences and Technologies, University of Campania Luigi Vanvitelli, Caserta, Italy.

Department of Experimental Medicine, University of Campania "L.Vanvitelli", Naples, Italy.

出版信息

Front Bioeng Biotechnol. 2024 Jul 9;12:1379574. doi: 10.3389/fbioe.2024.1379574. eCollection 2024.

DOI:10.3389/fbioe.2024.1379574
PMID:39055336
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11270027/
Abstract

subsp. HN019 is a commercially available well-characterized probiotic with documented effects on human health, such as the ability to enhance the immune function and to balance the intestinal microbiome. Therefore, optimizing the manufacturing process to improve sustainability, increasing biomass yields and viability, and avoiding animal -derived nutrients in the medium to meet vegan consumer's needs, is currently of interest. Besides the established use of live probiotic cells, alternative supplements indicated as postbiotics, like non-viable cells and/or probiotics derived bioactive molecules might be considered as potential next generation biotherapeutics. In fact, advantages of postbiotics include fewer technological limitations, such as easier production processes and scale-up, and even higher specificity. In this work, medium design together with different fermentation strategies such as batch, fed-batch and in situ product removal on lab-scale bioreactors were combined. Medium pretreatment by ultrafiltration and protease digestion was performed to reduce polysaccharidic contaminants and facilitate the purification of secreted exopolysaccharides (EPS). The latter were isolated from the fermentation broth and characterized through NMR, GC-MS and SEC-TDA analyses. The expression of TLR-4, NF-kb and IL-6 in LPS challenged differentiated CaCo-2 cells treated with EPS, live and heat-killed cells/broth, was evaluated by western blotting and ELISA. Zonulin was also assessed by immunofluorescence assays. The titer of viable HN019 was increased up to 2.9 ± 0.1 x 10 on an animal-free semidefined medium by applying an ISPR fermentation strategy. Medium pre-treatment and a simple downstream procedure enriched the representativity of the EPS recovered (87%), the composition of which revealed the presence of mannuronic acid among other sugars typically present in polysaccharides produced by bifidobacteria. The isolated EPS, live cells and whole heat inactivated broth were compared for the first up to date for their immunomodulatory and anti-inflammatory properties and for their ability to promote intestinal barrier integrity. Interestingly, EPS and live cells samples demonstrated immune-stimulating properties by downregulating the expression of TLR-4 and NF-kb, and the ability to promote restoring the integrity of the intestinal barrier by up-regulating the expression of zonulin, one of the tight junctions forming proteins. Postbiotics in the form of heat killed broth only reduced NF-kb expression, whereas they did not seem effective in the other tested conditions.

摘要

亚种HN019是一种市面上可买到的、特性明确的益生菌,对人体健康有诸多已被证实的作用,比如增强免疫功能和平衡肠道微生物群的能力。因此,目前人们感兴趣的是优化生产工艺以提高可持续性、提高生物量产量和活力,并避免培养基中使用动物源性营养成分以满足纯素消费者的需求。除了已确立的活益生菌细胞的用途外,作为后生元的替代补充剂,如无活力细胞和/或源自益生菌的生物活性分子,可能被视为潜在的下一代生物治疗剂。事实上,后生元的优势包括技术限制较少,如生产过程和扩大规模更容易,以及特异性更高。在这项工作中,将培养基设计与不同的发酵策略(如分批发酵、补料分批发酵和实验室规模生物反应器中的原位产物去除)相结合。通过超滤和蛋白酶消化进行培养基预处理,以减少多糖污染物并促进分泌型胞外多糖(EPS)的纯化。从发酵液中分离出后者,并通过核磁共振、气相色谱-质谱联用和尺寸排阻色谱-多角度光散射分析进行表征。通过蛋白质印迹法和酶联免疫吸附测定法评估了用EPS、活细胞和热灭活细胞/肉汤处理的脂多糖刺激的分化Caco-2细胞中TLR-4、NF-κB和IL-6的表达。还通过免疫荧光测定法评估了闭合蛋白。通过应用原位产物去除发酵策略,在无动物来源的半限定培养基上,HN019的活菌滴度提高到了2.9±0.1×10。培养基预处理和简单的下游程序提高了回收的EPS的代表性(87%),其组成显示除了双歧杆菌产生的多糖中通常存在的其他糖类外,还存在甘露糖醛酸。首次对分离出的EPS、活细胞和全热灭活肉汤的免疫调节和抗炎特性以及促进肠道屏障完整性的能力进行了比较。有趣的是,EPS和活细胞样本通过下调TLR-4和NF-κB的表达表现出免疫刺激特性,并通过上调闭合蛋白(一种形成紧密连接的蛋白质)的表达来促进恢复肠道屏障的完整性。热灭活肉汤形式的后生元仅降低了NF-κB的表达,而在其他测试条件下似乎没有效果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6886/11270027/c1059db8226f/fbioe-12-1379574-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6886/11270027/8a7498702ca7/fbioe-12-1379574-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6886/11270027/8c36f9cadcc5/fbioe-12-1379574-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6886/11270027/8ab1c7abf930/fbioe-12-1379574-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6886/11270027/122cfe48d899/fbioe-12-1379574-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6886/11270027/ebe6e8989a6c/fbioe-12-1379574-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6886/11270027/49593da08f99/fbioe-12-1379574-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6886/11270027/c1059db8226f/fbioe-12-1379574-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6886/11270027/8a7498702ca7/fbioe-12-1379574-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6886/11270027/8c36f9cadcc5/fbioe-12-1379574-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6886/11270027/8ab1c7abf930/fbioe-12-1379574-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6886/11270027/122cfe48d899/fbioe-12-1379574-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6886/11270027/ebe6e8989a6c/fbioe-12-1379574-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6886/11270027/49593da08f99/fbioe-12-1379574-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6886/11270027/c1059db8226f/fbioe-12-1379574-g007.jpg

相似文献

1
subsp. HN019 live probiotics and postbiotics: production strategies and bioactivity evaluation for potential therapeutic properties.亚种HN019活益生菌和后生元:潜在治疗特性的生产策略及生物活性评估
Front Bioeng Biotechnol. 2024 Jul 9;12:1379574. doi: 10.3389/fbioe.2024.1379574. eCollection 2024.
2
Impact of coculturing Bifidobacterium animalis subsp. lactis HN019 with yeasts on microbial viability and metabolite formation.将动物双歧杆菌乳酸亚种HN019与酵母共培养对微生物活力和代谢产物形成的影响。
J Appl Microbiol. 2017 Oct;123(4):956-968. doi: 10.1111/jam.13571. Epub 2017 Sep 11.
3
Gene Replacement and Fluorescent Labeling to Study the Functional Role of Exopolysaccharides in subsp. .基因替换与荧光标记法研究亚种中胞外多糖的功能作用
Front Microbiol. 2017 Jul 25;8:1405. doi: 10.3389/fmicb.2017.01405. eCollection 2017.
4
subsp. HN019 Effects on Gut Health: A Review.亚种 HN019 对肠道健康的影响:综述
Front Nutr. 2021 Dec 14;8:790561. doi: 10.3389/fnut.2021.790561. eCollection 2021.
5
Effects of Live and Heat-Inactivated Subsp. , BB-12 and GG on Caco-2 Cells.鼠李糖乳杆菌亚种、BB-12 和 GG 活菌和热处理菌对 Caco-2 细胞的影响。
Nutrients. 2020 Jun 8;12(6):1719. doi: 10.3390/nu12061719.
6
Impact of consumption of different levels of Bifidobacterium lactis HN019 on the intestinal microflora of elderly human subjects.不同水平的乳酸双歧杆菌HN019摄入对老年人体肠道微生物群的影响。
J Nutr Health Aging. 2007 Jan-Feb;11(1):26-31.
7
Exopolysaccharides produced by Bifidobacterium longum IPLA E44 and Bifidobacterium animalis subsp. lactis IPLA R1 modify the composition and metabolic activity of human faecal microbiota in pH-controlled batch cultures.长双歧杆菌 IPLA E44 和动物双歧杆菌亚种。乳双歧杆菌 IPLA R1 产生的胞外多糖改变了 pH 控制批次培养中人体粪便微生物群的组成和代谢活性。
Int J Food Microbiol. 2009 Nov 15;135(3):260-7. doi: 10.1016/j.ijfoodmicro.2009.08.017. Epub 2009 Aug 19.
8
Fermented or unfermented milk using Bifidobacterium animalis subsp. lactis HN019: Technological approach determines the probiotic modulation of mucosal cellular immunity.使用动物双歧杆菌乳酸亚种HN019的发酵或未发酵牛奶:技术方法决定了对黏膜细胞免疫的益生菌调节作用。
Food Res Int. 2014 Oct;64:283-288. doi: 10.1016/j.foodres.2014.05.036. Epub 2014 Jun 11.
9
Impact of Bifidobacterium animalis subsp. lactis HN019 probiotic in the prevention of periodontitis associated with immunosuppression.动物双歧杆菌乳亚种HN019益生菌在预防与免疫抑制相关的牙周炎中的作用
J Periodontol. 2023 Mar;94(3):389-404. doi: 10.1002/JPER.22-0146. Epub 2022 Dec 7.
10
Extraction of the same novel homoglycan mixture from two different strains of Bifidobacterium animalis and three strains of Bifidobacterium breve.从两株不同的动物双歧杆菌和三株短双歧杆菌中提取相同的新型同聚糖混合物。
Benef Microbes. 2018 Jun 15;9(4):663-674. doi: 10.3920/BM2017.0145. Epub 2018 Apr 26.

引用本文的文献

1
Development of a Strain-Specific Detection and Quantification Method for subsp. HN019 Using WGS-SNP Analysis and qPCR.利用全基因组测序单核苷酸多态性(WGS-SNP)分析和定量聚合酶链反应(qPCR)开发针对副溶血弧菌HN019亚种的菌株特异性检测和定量方法。
Microorganisms. 2025 Jul 7;13(7):1596. doi: 10.3390/microorganisms13071596.
2
Interconnection of the Gut-Skin Axis in NC/Nga Mouse with Atopic Dermatitis: Effects of the Three Types of CBT-BF3 (Probiotics, Postbiotics, and Cytosine-Phosphate-Guanine Oligodeoxynucleotide) on T Cell Differentiation and Gut Microbiota.NC/Nga 小鼠肠道-皮肤轴与特应性皮炎的关联:三种 CBT-BF3(益生菌、后生元及胞嘧啶-磷酸-鸟嘌呤寡脱氧核苷酸)对 T 细胞分化和肠道微生物群的影响
Food Sci Anim Resour. 2024 Nov;44(6):1417-1439. doi: 10.5851/kosfa.2024.e100. Epub 2024 Nov 1.

本文引用的文献

1
Next-Gen biotherapeutics: A systematic review and network meta-analysis on postbiotics as treatment for pediatric atopic dermatitis.下一代生物疗法:后生元治疗儿童特应性皮炎的系统评价和网络荟萃分析。
Pediatr Allergy Immunol. 2023 Sep;34(9):e14022. doi: 10.1111/pai.14022.
2
Postbiotics in the medical field under the perspective of the ISAPP definition: scientific, regulatory, and marketing considerations.基于国际益生菌与益生元科学协会(ISAPP)定义视角下医学领域中的后生元:科学、监管及市场考量
Front Pharmacol. 2023 Sep 8;14:1239745. doi: 10.3389/fphar.2023.1239745. eCollection 2023.
3
Optimizing postbiotic production through solid-state fermentation with J and SN4 enhances antibacterial, antioxidant, and anti-inflammatory activities.
通过与J和SN4进行固态发酵优化后生元生产可增强抗菌、抗氧化和抗炎活性。
Front Microbiol. 2023 Sep 7;14:1229952. doi: 10.3389/fmicb.2023.1229952. eCollection 2023.
4
Modulating the gut microbiota by probiotics, prebiotics, postbiotics, and fecal microbiota transplantation: An emerging trend in cancer patient care.通过益生菌、益生元、后生元及粪便微生物群移植调节肠道微生物群:癌症患者护理中的一个新趋势。
Biochim Biophys Acta Rev Cancer. 2023 Nov;1878(6):188990. doi: 10.1016/j.bbcan.2023.188990. Epub 2023 Sep 22.
5
Postbiotic as Novel Alternative Agent or Adjuvant for the Common Antibiotic Utilized in the Food Industry.后生元作为食品工业中常用抗生素的新型替代物或佐剂。
Curr Pharm Biotechnol. 2024;25(10):1245-1263. doi: 10.2174/1389201025666230912123849.
6
Heat-Killed Repairs Lipopolysaccharide-Induced Intestinal Epithelial Barrier Damage via MLCK/MLC Pathway Activation.热灭活通过肌球蛋白轻链激酶/肌球蛋白轻链途径激活修复脂多糖诱导的肠道上皮屏障损伤。
Nutrients. 2023 Apr 4;15(7):1758. doi: 10.3390/nu15071758.
7
Alternative culture medium design for biomass production of autochthonous meat starter Latilactobacillus sakei sp. sakei ACU-2.替代培养基设计用于土著肉发酵剂 sakei 亚种 Latilactobacillus sakei ACU-2 的生物量生产。
Sci Rep. 2023 Mar 30;13(1):5205. doi: 10.1038/s41598-023-29502-2.
8
Anti-Inflammatory and Gut Microbiota Modulating Effects of Probiotic MSMC39-1 on Dextran Sulfate Sodium-Induced Colitis in Rats.益生菌 MSMC39-1 对葡聚糖硫酸钠诱导的大鼠结肠炎的抗炎及调节肠道菌群作用。
Nutrients. 2023 Mar 13;15(6):1388. doi: 10.3390/nu15061388.
9
In Vitro Evaluation of the Most Active Probiotic Strains Able to Improve the Intestinal Barrier Functions and to Prevent Inflammatory Diseases of the Gastrointestinal System.能够改善肠道屏障功能并预防胃肠系统炎症性疾病的最具活性益生菌菌株的体外评估。
Biomedicines. 2023 Mar 12;11(3):865. doi: 10.3390/biomedicines11030865.
10
Exopolysaccharides of Lactobacillus rhamnosus GG ameliorate Salmonella typhimurium-induced intestinal inflammation via the TLR4/NF-κB/MAPK pathway.鼠李糖乳杆菌GG的胞外多糖通过TLR4/NF-κB/MAPK途径改善鼠伤寒沙门氏菌诱导的肠道炎症。
J Anim Sci Biotechnol. 2023 Mar 6;14(1):23. doi: 10.1186/s40104-023-00830-7.